SSX2 and synovial sarcoma: Moreover, the recent discovery of SSX fusions in synovial sarcoma with alternative activators, such as EWSR1 and MN1 (ref. 19), also raises questions about the requirement for direct BAF complex deregulation for all synovial sarcomas, prompting further investigation into the characteristics of the SSX tail.